UNSPSC 51142556: Melevodopa hydrochloride

This classification denotes a dopamine agonist with the molecular formula C10H13NO4.CLH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier JFU1A8866V. European Medicines Agency schedules melevodopa hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB33439. Most nations, for tariff and trade purposes, schedule melevodopa hydrochloride under HS 29225000. As of Q4 2014, MELEVODOPA HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: COC(=O)[C@H](CC1CCC(C(C1)O)O)N.CL.

UNSPSC 51142556 Melevodopa hydrochloride is a Commodity code that in practice covers pharmaceutical procurement by state and local health authorities, though recent opportunities show the code capturing a wider range of drug-supply activity than the nominal single-compound scope suggests. State and local health departments, county health systems, and multistate cooperative purchasing alliances solicit under this code for generic pharmaceuticals, naloxone, over-the-counter products, and direct-to-manufacturer pharmacy initiatives. Issuing bodies include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS), and cooperative purchasing consortia (Minnesota Multistate Cooperative Purchasing Alliance). The work involves establishing supply contracts with manufacturers and authorized wholesalers, managing National Drug Code specifications, compliance with cGMP and Drug Supply Chain Security Act requirements, and meeting quarterly or annual delivery schedules to health facilities.

Recent activity spans Florida, Texas, Minnesota, and Oregon. Three representative opportunities illustrate the current market: Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with a July 26, 2023 response deadline; the Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, to gather vendor capabilities for a Therapeutic Pharmacy Initiative direct-to-manufacturer prescription program; and the Minnesota Department of Administration's Office of State Procurement, administering MMCAP, issued RFP S1070000015802 on January 20, 2026, with a March 26, 2026 deadline to establish multiple contracts for generic multi-source pharmaceuticals and OTC products across participating state and local facilities. The MMCAP procurement emphasizes pricing competitiveness (75 percent of evaluation), compliance with authorized wholesaler relationships, and a 3 percent administrative fee on all contract purchases.